# Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma

> **NCT02955771** · PHASE2 · TERMINATED · sponsor: **Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.** · enrollment: 7 (actual)

## Conditions studied

- Hilar Cholangiocarcinoma

## Interventions

- **COMBINATION_PRODUCT:** PDT-Deuteporfin（6 hour)
- **COMBINATION_PRODUCT:** PDT-Deuteporfin（9 hour)
- **DEVICE:** stenting

## Key facts

- **NCT ID:** NCT02955771
- **Lead sponsor:** Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-17
- **Primary completion:** 2018-12-26
- **Final completion:** 2018-12-26
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2019-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02955771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02955771, "Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02955771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*